Treatment guidelines are now recognizing and suggesting immunotherapy for the treatment of several types of cancer.
However, Jeffrey Weber, MD, PhD, explains that the unspoken issue in regard to immunotherapies is that most are investigational. With respect to a payer covering treatment, in different states throughout the country, some will cover research-related costs and some will not.
As the panelists discuss how coverage inconsistencies, or the lack of coverage altogether, challenges providers to offer treatment as suggested by important NCCN guidelines, Daniel J. George, MD, concludes that there is no real way to develop a standard policy without reviewing each case individually.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Joanne Mizell: Lifestyle Modification Programs Take Holistic Aim at Metabolic Disease
May 1st 2024Joanne Mizell shares insurer strategies in addressing the escalating rates of metabolic diseases, highlighting the importance of holistic treatment methods like lifestyle modification programs, which integrate nutrition, physical activity, and community engagement.
Read More